• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Investigators study pathology of Usher syndrome


Usher syndrome 1G protein SANS regulates the splicing of genes, particularly those linked to Usher syndrome, which can lead to early vision loss form RP.

SANS is essential for the release of tri-snRNPs from the Cajal bodies and their transfer to the nuclear speckles. There the spliceosome is assembled and subsequently activated. Therefore, SANS plays a crucial role in correct pre-RNA splicing as a whole. Image courtesy of Uwe Wolfrum, PhD

SANS is essential for the release of tri-snRNPs from the Cajal bodies and their transfer to the nuclear speckles. There the spliceosome is assembled and subsequently activated. Therefore, SANS plays a crucial role in correct pre-RNA splicing as a whole. Image courtesy of Uwe Wolfrum, PhD

A team of investigators are conducting research into Human Usher syndrome (USH), a form of hereditary deaf-blindness.

The disease results from ciliopathy caused by mutations in the MYO7A gene. Patients diagnosed with the disease have congenital hearing loss, early vision loss from RP, and vestibular dysfunction.

The team is led by Uwe Wolfrum, PhD, of the Institute of Molecular Physiology at Johannes Gutenberg University Mainz (JGU). Working with a group headed up by Professor Reinhard Lührmann, PhD, at the Max Planck Institute for Biophysical Chemistry in Göttingen, the team has identified a novel pathomechanism leading to Usher syndrome.

According to a news release, the investigators have discovered that the Usher syndrome type 1G protein SANS plays a crucial role in regulating splicing process.

Furthermore, the researchers have been able to demonstrate that defects in the SANS protein can lead to errors in the splicing of genes related to the Usher syndrome, which may provoke the disease.

“We are aiming to elucidate the molecular basis that leads to the degeneration of the light-sensitive photoreceptor cells in the eye in cases of Usher syndrome,” Wolfrum explained in the release.

For patients diagnosed with USH, cochlea implants can be used to compensate for hearing loss. However, there are currently no existing treatments for the associated blindness.

The current investigation is focusing on one of the Usher syndrome proteins, the USH1G protein, known as SANS. Previous research undertaken by Wolfrum's team established that SANS acts as a scaffold protein.

Investigators noted that SANS has multiple domains to which other proteins can dock, thus ensuring correct cellular function. Mutations in the USH1G/SANS gene lead to malfunctions of the auditory and vestibular hair cells in the inner ear and of the photoreceptor cells of the retina, which are responsible for the sensory defects experienced by patients with Usher syndrome.

It remains unclear how SANS contributes to pathogenic processes in the eye. Encoded by the USH1G gene, the protein is expressed in the photoreceptors of the retina and glia cells.

“So far, we had thought of SANS simply as a scaffold molecule that participates in transport processes in the cytoplasm associated with ciliary extensions,” Wolfrum said in the release. “But recently, Adem Yildirim in his doctoral thesis conducted in the International PhD Program (IPP) in Mainz discovered that SANS interacts with splicing factors to regulate pre-mRNA splicing.”

SANS regulates the splicing of pre-mRNA
Wolfrum explained that splicing is a key process in path from the coding gene to the biosynthesis of proteins.

During splicing, non-coding introns are removed from initially transcribed pre-mRNA or, in the case of alternative splicing, exons that are not required for the subsequent protein variant are excluded.

The resulting mRNA is then used for protein biosynthesis. The splicing process is catalyzed in the nucleus by the spliceosome, a dynamic, highly complex molecular machine that is successively assembled during the splicing process from a number of subcomplexes of protein and RNA components.

“We were surprised by our finding that SANS is not only a component of the transport to cilia at the surface of the cell but also active in the nucleus and can modulate the splicing process there too,” Wolfrum said.

In the cell nucleus, SANS is responsible for transferring tri-snRNP complexes, or components of spliceosome subcomplexes, from the Cajal bodies, a kind of molecular assembly line, to the so-called nuclear speckles.

In this compartment, investigators found that tri-snRNP complexes bind to the spliceosome assembly to subsequently activate it. SANS is also likely to be involved in recycling the tri-snRNP components back to the Cajal bodies.

The absence of SANS and also pathogenic mutations of the USH1G/SANS gene prevent the spliceosome being correctly assembled and sequentially activated.

This, in turn, suppresses the correct splicing of other Usher syndrome-related genes, ultimately leading to their dysfunction and therefore to the development of the disorder.

Investigators pointed out that they offered the first evidence that splicing dysregulation may participate in the pathophysiology of Usher syndrome.

“In addition to the new findings relating to the splicing mechanism, we have also identified new aspects that we aim to investigate with regard to developing concepts for the treatment and therapy of the Usher syndrome in future.,” Wolfrum concluded.

In other studies, investigators are examining antisense oligonucleotide therapy for the treatment of Usher syndrome due to mutations in exon 13 of the USH2A gene. Choroideremia is also the subject of multiple ongoing gene therapy trials.

Related Videos
Jay Barth, MD
Moving beyond the drop: CEO provides updates on Oyster Point's pipeline
Stargardt research: Therapy on the horizon for inherited retinal disease
© 2024 MJH Life Sciences

All rights reserved.